Skip to main content
All lobbying filings

PFIZER INC.

PFIZER INC. filed a Q2 report for PFIZER INC. on July 20, 2026.

Lobbying for PFIZER INC.

All filings by PFIZER INC. · Everything PFIZER INC. has reported

 Filing · LD-2 quarterly report Q2 report
Reporting period
2nd Quarter 2026
Apr 1 - June 30 · Posted Jul 20, 2026
Expenses
$1,880,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
District of Columbia

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5
Copyright/Patent/Trademark

Intellectual Property Protections and Policy S. 2658 - Medication Affordability and Patent Integrity Act

Health Issues

Vaccine Coverage and Coverage Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Codification and Sec. 301 trade investigations FDA User Fee Agreements: 2027 PDUFA Cycle H.R. 7837 - Most Favored Patient Act of 2026 H.R. 7391 - Community Health Center Drug Pricing Protection Act 340B Program Reform Inflation Reduction Act (IRA) H.R. 8646 - Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriates Act, 2027 H.R. 9260 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriation Act, 2027 H.R. 5178 - Sickle Cell Disease Comprehensive Care Act H.R. 5526 - Biosimilars Red Tape Elimination Act H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade H.R. 4299 - Protecting Patient Access to Cancer and Complex Therapies Act: IRA reforms Prior Authorization Step Therapy Practices FDA Modernization and Reforms Drug Pricing PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage

Medicare/Medicaid

H.R. 7391 - Community Health Center Drug Pricing Protection Act Executive Order 14297 - Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Vaccine Access and Coverage 340B Program Reform PBM Reform Direct-to-Patient Prescription Drug Purchase Platforms and Insurance Coverage Step Therapy Practices Drug Pricing Medicare/Medicaid Issues

Taxation/Internal Revenue Code

H.R. 1 - An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14

Trade (domestic/foreign)

H.R. 9102 - Biotech Investment National Security Act (BINSA) Act: US Competitiveness, Biotechnology H.R. 4930 - To Expand the Sharing of Information with Respect to Suspected Violations of Intellectual Property Rights in Trade International Supply Chain Section 301 Investigation re: Germany Issues Market Access Most Favored Nation Policies Foreign Freeriding Issues Non-Tariff Trade Barriers Competitiveness Issues Trade Issues

 Bills named in this filing 12
  • S. 2658
    Medication Affordability and Patent Integrity Act
  • H.R. 7837
    Most Favored Patient Act of 2026
  • H.R. 7391
    Community Health Center Drug Pricing Protection Act
  • H.R. 8646
    Agriculture, Rural Development, Food and Drug Administration, and Related Agency Appropriations Act, 2027
  • H.R. 9260
    Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027
  • H.R. 5178
    Sickle Cell Disease Comprehensive Care Act
  • H.R. 5526
    Biosimilar Red Tape Elimination Act
  • H.R. 4930
    To expand the sharing of information with respect to suspected violations of intellectual property rights in trade.
  • H.R. 4299
    Protecting Patient Access to Cancer and Complex Therapies Act
  • H.R. 1
    One Big Beautiful Bill Act
  • H. Con. Res. 14
    Establishing the congressional budget for the United States Government for fiscal year 2025 and setting forth the appro…
  • H.R. 9102
    BINSA Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem